DASL-HICAP
Start here
An interim analysis of the phase III DASL-HiCaP trial, presented at ESMO 2026, tested darolutamide added to radiotherapy and androgen deprivation therapy in patients with high-risk localized prostate cancer. The randomized study enrolled 1106 patients. At a median follow-up of 3.8 years, the combination reduced the risk of metastasis or death by 58% compared with the control arm, with 4-year MFS-CI rates of 95% versus 88% (HR 0.42, 95% CI 0.27–0.66, p=0.0001). The results position darolutamide as an intensification option for this earlier-stage setting. Full publication and longer-term outcomes are still awaited.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comDASL-HiCaP Phase III Interim Analysis: Darolutamide Plus Radiotherapy and ADT Cuts Metastasis or Death Risk 58% in High-Risk Localized Prostate Cancer
An interim analysis of the randomized phase III DASL-HiCaP trial, presented at ESMO 2026, showed that darolutamide added to radiotherapy and ADT reduced the risk of metastasis or death by 58% in patients with high-risk localized prostate cancer. The study (NCT04136353, ANZUP1801) enrolled 1106 patients; at a median follow-up of 3.8 years, the 4-year MFS-CI rates were 95% versus 88% (HR=0.42, 95% CI 0.27–0.66, p=0.0001).
- x.com#ESMO2026
- x.comDASL-HiCaP #ESMO26
Heat trend for this story
Heat now 111·Peak in the comparable set 129 (Oct 25 11:00)·Change over 24h in the comparable set -1%·Participants now 28
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.